Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

8th April 2020 Uncategorised 0

With Roche’s SMA candidate risdiplam stalled at the FDA for three more months, it’s a reprieve for the two therapies it would have threatened—Biogen’s Spinraza and Novartis’ gene therapy Zolgensma. But the relief could be short-lived, and might even work to Roche’s favor in the end.

More: Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Source: fierce